Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients

Podobne knjige/članki

• The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients
  od: Knechten, H, et al.
  Izdano: (2011)
• Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
  od: Knechten, Heribert, et al.
  Izdano: (2010)
• Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen
  od: von Hentig, Nils, et al.
  Izdano: (2007)
• The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
  od: Wiesmann, Frank, et al.
  Izdano: (2011)
• Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro
  od: Skinner-Adams, T. S., et al.
  Izdano: (2007)